Taken together, we presented an integrative strategy utilizing PATH-SURVEYOR to prioritize pathways based on patient risk and identified known therapeutic targets in high-risk KMT2A fusion-positive AML patients. This evidence concerns the gene KMT2A and acute myeloid leukemia.